Observational Trial on Long Responses in Patients With Advanced Non-Small Cell Lung Cancer Treated in Second-Line With Erlotinib
Observational Trial on Long Responses in Patients With Advanced Non-Small Cell Lung Cancer Treated in Second-Line With Erlotinib
This multicenter, retrospective and prospective observational, cohort study will examine the effect of second-line Tarceva treatment on long response in non-small cell lung cancer (NSCLC) participants with wild type or unknown EGFR status. Participants will be observed from the start of treatment for 8 months or until death. The extension of the retrospective versus prospective observation will depend on the lag between the date of the participant enrollment and the date of beginning of erlotinib therapy.
Inclusion Criteria:
Exclusion Criteria:
Naples, Campania 80131, Italy
Naples, Campania 80131, Italy
Meldola, Emilia-Romagna 47014, Italy
Rome, Lazio 00152, Italy
Rome, Lazio 00161, Italy
Genoa, Liguria 16132, Italy
Palermo, Sicily 90146, Italy
Pisa, Tuscany 56124, Italy